Risankizumab has been shown to be efficacious and safe in patients with plaque psoriasis who have a suboptimal response to IL-17 inhibitors.

Sleep disturbances in adults with moderate-to-severe AD generally improve over time.

New findings show that AD incidence and prevalence have increased over the last two decades, especially in Black and multiracial children.

There is no increased risk of infections in pediatric psoriasis patients treated with ustekinumab compared to etanercept or methotrexate.

On the newest episode of Shear Listening Pleasure, Dr. Shear speaks with DiTiDE essay competition winner Dr. Samantha Bizimungu.

Psoriasis patients are significantly more likely to experience migraines than those without psoriasis.

Dupilumab was effective in improving disease severity and decreasing severity-associated serum biomarkers in pediatric AD patients.

A new study has evaluated the worldwide prevalence of mental disorders such as depression, anxiety, and suicide in patients with psoriasis.